The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
The outcome of high-dose chemotherapy (HDT) was evaluated retrospectively in 27 patients with myeloma and four patients with AL amyloidosis with severe renal impairment. Twenty-three patients were receiving dialysis and the rest had a creatinine clearance of <20 ml/min. The median melphalan d...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1797095422243635200 |
|---|---|
| author | Bird, J Fuge, R Sirohi, B Apperley, J Hunter, A Snowden, J Mahendra, P Milligan, D Byrne, J Littlewood, T Fegan, C McQuaker, G Pagliuca, A Johnson, P Rahemtulla, A Morris, C Marks, D |
| author_facet | Bird, J Fuge, R Sirohi, B Apperley, J Hunter, A Snowden, J Mahendra, P Milligan, D Byrne, J Littlewood, T Fegan, C McQuaker, G Pagliuca, A Johnson, P Rahemtulla, A Morris, C Marks, D |
| author_sort | Bird, J |
| collection | OXFORD |
| description | The outcome of high-dose chemotherapy (HDT) was evaluated retrospectively in 27 patients with myeloma and four patients with AL amyloidosis with severe renal impairment. Twenty-three patients were receiving dialysis and the rest had a creatinine clearance of <20 ml/min. The median melphalan dose was 140 mg/m2 (range: 60-200 mg/m2), but 10 patients (37%) received 200 mg/m2. Myeloid and platelet engraftment were similar to that seen in patients without renal failure. Five of 27 patients died of transplant-related toxicity before the day 100. Twenty of 27 patients had a response (70%). The median time to disease progression was 32 months (range: 6-54 months) and the median time to best response was 6.5 months. Four of 17 evaluable patients (24%) became dialysis-independent at a median of 5 months post-HDT/stem cell transplantation. At a median follow-up of 70 months, 7/23 patients with myeloma were alive but three of these seven patients had progressive disease. Two of the four patients with amyloidosis have survived. HDT is feasible in these patients and results in 5-year survival in about one-third of patients. |
| first_indexed | 2024-03-07T04:27:37Z |
| format | Journal article |
| id | oxford-uuid:cd32964c-c9b1-47ae-a445-15192b5960d6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:27:37Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:cd32964c-c9b1-47ae-a445-15192b5960d62022-03-27T07:27:06ZThe clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cd32964c-c9b1-47ae-a445-15192b5960d6EnglishSymplectic Elements at Oxford2006Bird, JFuge, RSirohi, BApperley, JHunter, ASnowden, JMahendra, PMilligan, DByrne, JLittlewood, TFegan, CMcQuaker, GPagliuca, AJohnson, PRahemtulla, AMorris, CMarks, DThe outcome of high-dose chemotherapy (HDT) was evaluated retrospectively in 27 patients with myeloma and four patients with AL amyloidosis with severe renal impairment. Twenty-three patients were receiving dialysis and the rest had a creatinine clearance of <20 ml/min. The median melphalan dose was 140 mg/m2 (range: 60-200 mg/m2), but 10 patients (37%) received 200 mg/m2. Myeloid and platelet engraftment were similar to that seen in patients without renal failure. Five of 27 patients died of transplant-related toxicity before the day 100. Twenty of 27 patients had a response (70%). The median time to disease progression was 32 months (range: 6-54 months) and the median time to best response was 6.5 months. Four of 17 evaluable patients (24%) became dialysis-independent at a median of 5 months post-HDT/stem cell transplantation. At a median follow-up of 70 months, 7/23 patients with myeloma were alive but three of these seven patients had progressive disease. Two of the four patients with amyloidosis have survived. HDT is feasible in these patients and results in 5-year survival in about one-third of patients. |
| spellingShingle | Bird, J Fuge, R Sirohi, B Apperley, J Hunter, A Snowden, J Mahendra, P Milligan, D Byrne, J Littlewood, T Fegan, C McQuaker, G Pagliuca, A Johnson, P Rahemtulla, A Morris, C Marks, D The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. |
| title | The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. |
| title_full | The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. |
| title_fullStr | The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. |
| title_full_unstemmed | The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. |
| title_short | The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. |
| title_sort | clinical outcome and toxicity of high dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment a british society of blood and marrow transplantation study |
| work_keys_str_mv | AT birdj theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT fuger theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT sirohib theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT apperleyj theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT huntera theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT snowdenj theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT mahendrap theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT milligand theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT byrnej theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT littlewoodt theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT feganc theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT mcquakerg theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT pagliucaa theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT johnsonp theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT rahemtullaa theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT morrisc theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT marksd theclinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT birdj clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT fuger clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT sirohib clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT apperleyj clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT huntera clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT snowdenj clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT mahendrap clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT milligand clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT byrnej clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT littlewoodt clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT feganc clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT mcquakerg clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT pagliucaa clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT johnsonp clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT rahemtullaa clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT morrisc clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy AT marksd clinicaloutcomeandtoxicityofhighdosechemotherapyandautologousstemcelltransplantationinpatientswithmyelomaoramyloidandsevererenalimpairmentabritishsocietyofbloodandmarrowtransplantationstudy |